Download Files:
Linifanib
$55 – $1,320
Products Details
Product Description
– Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis[1][2].
Web ID
– HY-50751
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C21H18FN5O
References
– [1]Albert DH, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther, 2006, 5(4), 995-1006.|[2]Monroig-Bosque PDC, et al. OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep. 2018;8(1):13106. Published 2018 Aug 30.|[3]Banchi M, et al. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer. Am J Cancer Res. 2020;10(7):2120-2127. Published 2020 Jul 1.
CAS Number
– 796967-16-3
Molecular Weight
– 375.40
Compound Purity
– 99.72
SMILES
– O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 13.16 mg/mL (ultrasonic)
Target
– Apoptosis;Autophagy;c-Fms;c-Kit;FLT3;PDGFR;VEGFR
Isoform
– PDGFRβ;VEGFR1/Flt-1;VEGFR2/KDR/Flk-1
Pathway
– Apoptosis;Autophagy;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
